Navigation Links
Lixte Biotechnology Holdings, Inc. Awarded Grant Under Qualifying Therapeutic Discovery Project from the U. S. Government
Date:3/2/2011

EAST SETAUKET, N.Y., March 2, 2011 /PRNewswire/ -- Lixte Biotechnology Holdings (OTC: LIXT) announced today that the company has received a $244,479.25 grant under the Qualifying Therapeutic Discovery Project (QTDP).  This grant was awarded to further development and commercialization of Lixte's novel anti-cancer compound LB-100.  The QTDP program was included as part of the Patient Protection and Affordable Care Act of 2010 to encourage development of new therapies to prevent, diagnose, and treat acute and chronic diseases.  The selection process took into consideration the potential of projects to reduce long-term healthcare costs in the United States or significantly advance the goal of curing cancer over the next 30 years.  The selections were made jointly by the Department of Health and Human Services and the Treasury Department.  

"We are extremely pleased to have qualified for this grant," said Dr. John Kovach, founder and president of Lixte. "The funds will be used as part of our effort to complete pre-clinical studies and submit an IND to the FDA to bring our novel compound LB-100 to Phase I clinical trial. LB-100 represents a new type of anti-cancer drug, which we hope will improve treatments for several different types of human cancers for which more effective therapies are urgently needed."

About Lixte Biotechnology Holdings, Inc:Lixte Biotechnology Holdings, Inc. is a cancer therapeutics company. Founded as a biomarker-diagnostics company in 2005, Lixte primary focus is discovery of new chemotherapy drugs based on targeting molecular abnormalities of common human cancers critical to their survival.

Forward-Looking StatementsThis announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regardin
'/>"/>

SOURCE Lixte Biotechnology Holdings
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Lixte Biotechnology Holdings, Inc. Announces the Approval of a Collaboration with the National Cancer Institute for Clinical Evaluation of its Lead Anti-Cancer Compound, LB-100.
2. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
3. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
4. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
5. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
6. Pharma ChemOutsourcing Targets BioNJ, PA Bio, MassBio, BayBio, SoCalBio, and NY Biotechnology Association Member Companies for September 2011 Show in New Jersey
7. Reportlinker Adds Global Biotechnology Instrumentation Industry
8. NASDAQ Removes TLCR From Biotechnology Index Pending FTC Decision on Grifols Acquisition
9. Reportlinker Adds Global Agricultural Biotechnology Industry
10. Champions Biotechnology Awarded $1.46 million in Grants
11. Goodwin Biotechnology Announces Signing New Biopharmaceutical Development & Manufacturing Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)...  Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ) ... (FDA) accepted the company,s Investigational New Drug (IND) application ... efficacy of AVP-786, Avanir,s next generation compound. The company ... adjunctive treatment of major depressive disorder (MDD) during the ... endorsement of this Phase II study by the division ...
(Date:7/21/2014)... 21, 2014 Sorrento Therapeutics, Inc. (NASDAQ: ... developing new treatments for cancer and its associated pain, ... the preclinical development of a small molecule inhibitor targeting ... The Myc protein has also been recognized as an ... is involved as a dominant factor in most human ...
(Date:7/21/2014)... LA JOLLA, Calif. , July 21, 2014 ... RGLS ), a biopharmaceutical company leading the discovery ... today that the U.S. Food & Drug Administration ... a single stranded, chemically modified oligonucleotide that binds ... as a therapeutic for the treatment of Alport ...
Breaking Medicine Technology:Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 2Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 3Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 4Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 5Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor 2Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor 3Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor 4Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 2Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 3Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 4Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 5
... Inc. (OTCPK: SNDY) is pleased to announce that the Company ... in the amount of $90,005. The revenue for the three ... fifty Hospitals, Clinics, Healthcare Centers, Medical Centers and Surgery Centers ... growth in 2011 through new product development, new product sales ...
... Ireland, Jan. 27, 2011 Tibotec Pharmaceuticals today ... to generic manufacturers including Hetero Drugs Limited, Matrix ... Aspen Pharmacare of South Africa to manufacture, market ... rilpivirine hydrochloride (TMC278), pending ...
Cached Medicine Technology:Solos Endoscopy, Inc. Reports $90,005 in Sales Revenue for Fourth Quarter 2010 2Tibotec Signs Multiple Agreements With Generic Manufacturers to Provide Access to New HIV Treatment 2Tibotec Signs Multiple Agreements With Generic Manufacturers to Provide Access to New HIV Treatment 3Tibotec Signs Multiple Agreements With Generic Manufacturers to Provide Access to New HIV Treatment 4
(Date:7/22/2014)... (PRWEB) July 22, 2014 Garland’s new ... is designed to be used as a flood coat ... systems or as a premium restoration material. It provides ... the long-term performance and reducing life-cycle costs. Energizer BK ... to provide excellent water resistance in addition to superior ...
(Date:7/22/2014)... The hair transplant experts at WeGrowHair.com ... assisted laser therapy and robotic assisted hair transplantation ... women suffering from hair loss. Alongside their unique ... Unit Extraction (FUE) procedures via ARTAS – the ... technology, their doctors use advanced digital mapping to ...
(Date:7/21/2014)... sports in the United States, with more than 170,000 ... participation numbers, however, mean that more young people than ... and competition. , In a study published online today ... and available in an upcoming print issue, researchers from ... Children,s Hospital and the Colorado School of Public Health ...
(Date:7/21/2014)... July 21, 2014 As reported by ... Westin Hotel to Raise Addiction Awareness (7/15), thrill-seeking participants ... down a 27-story building in Downtown Philly. 100 people, ... event at the Westin Convention Center Hotel. Some of ... addiction. One man participated because his son killed himself ...
(Date:7/21/2014)... who have a clot in their legs and ... blood-thinning medication or undergo a minimally-invasive catheter-based clot ... no difference in death rates between the two ... the catheter procedure, according to a study by ... involved a review of more than 90,000 cases ...
Breaking Medicine News(10 mins):Health News:Energizer® BK Waterproof Coating from Garland Canada Reduces Life-Cycle Costs 2Health News:WeGrowHair.com/PAI Medical Group Introduces Robotic Assisted Laser Therapy to Treat Hair Loss 2Health News:New study finds high school lacrosse players at risk for concussions, other injuries 2Health News:New study finds high school lacrosse players at risk for concussions, other injuries 3Health News:100 People Climb Down Building to Raise Drug Addiction Awareness in Philadelphia 2Health News:100 People Climb Down Building to Raise Drug Addiction Awareness in Philadelphia 3Health News:Temple study compares deep vein thrombosis therapies 2Health News:Temple study compares deep vein thrombosis therapies 3Health News:Temple study compares deep vein thrombosis therapies 4
... international HIV and AIDS charity AVERT is today launching Stop ... to the 380,000 child AIDS deaths and half a ... ,At this year's G8 summit in Germany, the leaders ... to stop child AIDS deaths by committingspecific funds for prevention ...
... mental well being of young children of today seems to ... NCH, the childrens charity, found that one in ten ... significant level. ,The research says that More than a ... number in a generation. Emotional problems and conduct disorders have ...
... Washington University School of Medicine in St. Louis have ... by revealing that smoking interferes with ligament healing. ... model and found that cigarette smoking impairs the recruitment ... following ligament repair surgery. ,The researchers ...
... More than 60 people had to be treated in hospital ... a polluted Chinese river, state media reported Wednesday. ... their clothes in the Jindong River in eastern Anhui province ... few hours later, Xinhua news agency reported. ,The ...
... have found that a particular resonance pattern in the ... ability to discriminate speech. ,In the ... and Huan Luo report that the inherent rhythm of ... sentences by changing its phase. ,The researchers ...
... recalls how she lost her father, mother and father-in-law to ... to Panama from China. "It's very painful. The three had ... she says, her voice shaking with emotion. ,The ... found to be tainted. At least 80 people in Panama ...
Cached Medicine News:Health News:AIDS Charity AVERT Launches Stop AIDS in Children Campaign 2Health News:Mental Health of Children on the Decline 2Health News:Smoking Hampers Healing of the Ligament 2Health News:Dozens of Panamanians Gravely Ill from Toxic Substance from China 2